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Abstract
Lipid-based nutrient supplements (LNS) may be beneﬁcial for malnourished HIV-infected patients starting antiretroviral therapy (ART). We assessed the
effect of adding vitamins and minerals to LNS on body composition and handgrip strength during ART initiation. ART-eligible HIV-infected patients with
BMI <18·5 kg/m2 were randomised to LNS or LNS with added high-dose vitamins and minerals (LNS-VM) from referral for ART to 6 weeks post-ART
and followed up until 12 weeks. Body composition by bioelectrical impedance analysis (BIA), deuterium (2H) diluted water (D2O) and air displacement
plethysmography (ADP), and handgrip strength were determined at baseline and at 6 and 12 weeks post-ART, and effects of LNS-VM v. LNS at 6 and
12 weeks investigated. BIA data were available for 1461, D2O data for 479, ADP data for 498 and handgrip strength data for 1752 patients. Fat mass
tended to be lower, and fat-free mass correspondingly higher, by BIA than by ADP or D2O. At 6 weeks post-ART, LNS-VM led to a higher
regain of BIA-assessed fat mass (0·4 (95 % CI 0·05, 0·8) kg), but not fat-free mass, and a borderline signiﬁcant increase in handgrip strength (0·72
(95 % CI −0·03, 1·5) kg). These effects were not sustained at 12 weeks. Similar effects as for BIA were seen using ADP or D2O but no differences reached
statistical signiﬁcance. In conclusion, LNS-VM led to a higher regain of fat mass at 6 weeks and to a borderline signiﬁcant beneﬁcial effect on handgrip
strength. Further research is needed to determine appropriate timing and supplement composition to optimise nutritional interventions in malnourished
HIV patients.
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*Corresponding author: George PrayGod, fax +255 28 2500654, email gpraygod@yahoo.com
© The Author(s) 2019. This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-
NoDerivatives licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in
any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for
commercial re-use or in order to create a derivative work.
JNS
JOURNAL OF NUTRITIONAL SCIENCE
1Do
w
nl
oa
de
d 
fr
om
 h
tt
ps
:/
/w
w
w
.c
am
br
id
ge
.o
rg
/c
or
e.
 U
C
L,
 In
st
itu
te
 o
f E
du
ca
tio
n,
 o
n 
04
 Ju
n 
20
19
 a
t 1
5:
50
:0
7,
 s
ub
je
ct
 to
 th
e 
C
am
br
id
ge
 C
or
e 
te
rm
s 
of
 u
se
, a
va
ila
bl
e 
at
 h
tt
ps
:/
/w
w
w
.c
am
br
id
ge
.o
rg
/c
or
e/
te
rm
s.
 h
tt
ps
:/
/d
oi
.o
rg
/1
0.
10
17
/j
ns
.2
01
9.
15
HIV infection continues to be a major public health problem
in sub-Saharan Africa(1). Despite increased access to antiretro-
viral therapy (ART) in countries in Africa, about 15–30 % of
patients(2,3) attending ART clinics are malnourished due to
nutritional problems associated with advanced HIV infec-
tion(4). Food insecurity resulting from HIV infection may
aggravate the problem, since HIV-infected patients and their
families may have reduced capacity to produce or afford
nutritionally adequate food(5).
Malnutrition, particularly wasting of lean mass (used here
synonymously with fat-free mass), is associated with delayed
clinical and functional recovery, and increased risk of mortality
among patients starting ART(2,6,7). With the goal of improving
nutritional rehabilitation and survival, prior randomised con-
trolled trials have investigated the role of macronutrient and
micronutrient supplementation on health and mortality of
HIV-infected patients(8,9). In some but not all macronutrient
trials, these interventions have been shown to have beneﬁts
on the health of HIV patients. For example, a trial in
Ethiopia among malnourished HIV-infected patients found
that both whey- and soya-based supplementary foods
increased fat-free mass measured by the deuterium (2H)
diluted water (D2O) technique among patients with viral sup-
pression at 3 months following these interventions(10) and in
Malawi malnourished HIV-infected patients receiving
ready-to-use fortiﬁed spread had higher gain in fat-free mass
compared with those on a corn–soya blend(11). However,
most of the micronutrient trials showed no, limited or only
short-term beneﬁts during HIV care. Part of the reasons for
such limited effects may be that some studies were conducted
in settings where malnutrition including micronutrient deﬁ-
ciency is not prevalent among the HIV-infected population(9).
Some discrepancies among results may also be due to differ-
ent techniques used to assess body composition. The bioelec-
trical impedance analysis (BIA) method is simple and cheap to
apply, and hence can be used in large sample sizes. Although it
provides acceptable results, it has lower accuracy in individuals
compared with reference methods such as air displacement
plethysmography (ADP) or D2O
(12,13) which measure tissue
masses directly; however, ADP and D2O are expensive and
may be difﬁcult logistically to administer. Given contrasting
strengths and limitations of these methods, using more than
one method may help to better understand the effect of inter-
ventions on body composition. As potential differences
between HIV-infected patients and normal healthy adults in
lean tissue properties (e.g. hydration) may have an impact on
direct body composition assessment, further information can
be gained through assessment of grip strength, a functional
indicator of fat-free mass which is reduced in malnutrition
and which is inversely associated with survival(14,15).
In the Nutritional Support for African Adults Starting
Antiretroviral Therapy (NUSTART) trial, we found that vita-
mins and minerals added to lipid-based nutrient supplements
(LNS-VM) increased cluster of differentiation 4 (CD4) count
and some anthropometric measures by 12 weeks of
ART(16,17). In the present paper we examine the effects of
LNS-VM, compared with LNS, on grip strength and body
composition. We hypothesised that the intervention would
have beneﬁcial effects on handgrip strength and fat-free
mass since it contained nutrients including Zn, P and Mg
which are essential for repletion of muscle and organs(18).
Methods
Study setting
The study was conducted fromAugust 2011 to December 2013
at the National Institute for Medical Research (NIMR),
Mwanza, Tanzania and the University Teaching Hospital
(UTH), Lusaka, Zambia. In Mwanza HIV-infected patients
were screened at six peripheral ART clinics and recruitment
was conducted at a research clinic located at the Sekou-Toure
Regional Hospital. In Lusaka patients were recruited from six
peripheral ART clinics and were referred to UTH for enrol-
ment. HIV diagnosis and treatment followed local national
guidelines(19,20). The trial was registered at the Pan African
Clinical Trials Registry as PACTR201106000300631 (http://
www.pactr.org).
Inclusion and exclusion criteria
HIV-infected patients who were being referred for ART in
Mwanza and Lusaka were included in the trial if they met
the following criteria: age 18 years and above, ART-naive
(except for standard short-course regimens to prevent
maternal-to-child HIV transmission), undernourished (BMI
<18·5 kg/m2), eligible for ART according to national criteria
at the time (CD4 count <350 cells/μl or had WHO stage 3
or 4 disease), willing to undertake intensive ART follow-up
in the study clinic, and provided written informed consent.
Patients were not invited into the trial if they were participating
in a similar study or were pregnant by self-report.
Study design and interventions
The NUSTART study was a phase III randomised controlled
trial comparing in a two-stage protocol LNS-VM (intervention)
v. LNS (control) given from recruitment at referral for ART
until 6 weeks after starting ART(16). In the ﬁrst stage, from
recruitment to 2 weeks after starting ART, participants in the
control or treatment intervention were given 30 g/d LNS or
LNS-VM, about 150 kcal (630 kJ)/d, and in the second stage,
from 2–6 weeks after initiating ART, participants were given
250 g/d LNS or LNS-VM, about 1400 kcal (5860 kJ)/d. The
LNS was manufactured for the trial by Nutriset (Malaunay,
France) and came in ready-to-eat packets. Due to high nutrient
requirements in HIV patients, the amounts of added vitamins
and minerals in LNS-VM were three times the Recommended
Nutrient Intake (RNI) for British women(21), but to avoid
possible deleterious effects of Fe during severe infections(22),
Fe was not included in the ﬁrst stage, and in the second stage
we provided one RNI only. We included bulk minerals, i.e. K,
Mg and P, in both stages to address deﬁciencies of these miner-
als, correct electrolyte imbalance and promote tissue repletion.
Further details of the intervention are in Supplementary
Table S1 and published(16).
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Outcomes
The primary trial outcome was mortality between recruitment
and 12 weeks post-ART initiation(16). Secondary outcomes pre-
sented here include effects on handgrip strength, fat mass and
fat-free mass at 6 and 12 weeks post-ART initiation and during
the follow-up period. BIA results were used as our main meas-
ure of body composition, both because we had results for the
greatest proportion of participants and because it is a relatively
cheap and feasible technique even in fairly poorly resourced
settings. BIA produces results predicted from impedance, age,
sex, weight and height and we wished to compare these results
with the more direct measurements given by ADP and D2O.
Randomisation, allocation concealment and blinding
Randomisation was conducted by the Data and Safety
Monitoring Board (DSMB) statistician using computer-
generated blocks of sixteen and stratiﬁed by country.
Packages of LNS-VM and LNS, in both small- and large-dose
formats, were delivered by the producer in lots designated by
allocation code. Clinic pharmacists not involved in recruitment
or provision of care to study participants labelled intervention
packets with the study identity numbers at the time packets
were dispensed. Participants were recruited by clinic nurses
with no access to the code and assigned sequential identity num-
bers (within sites) after they were found to be eligible and had
signed informed consent. Both participants and recruiting
staff were not aware of the group of the dispensed supplements
and intervention and control supplements packets were of equal
size, colour, and similar taste. Adherence to study supplements
was modest, with only 39 % of participants consuming at least
75 % of their expected number of sachets of supplement(16).
Sample size justification
As we reported earlier, by the end of recruitment, we had
recruited 1815 patients(16). This number was sufﬁcient to
detect, at 5 % signiﬁcance, 90 % power and 25 % attrition
by 12 weeks due to death or loss to follow-up, differences
of 0·18 of a standard deviation in secondary continuous out-
comes measured at 6 and 12 weeks.
Ethics
The study was conducted according to principles laid down in the
Declaration ofHelsinki. Ethics committees of the London School
of Hygiene & Tropical Medicine, the University of Zambia
Biomedical Research Ethics Committee, and the Medical
Research Coordinating Committee of NIMR, Tanzania provided
ethics clearances. Patients were enrolled after providing written or
thumbprint informed consent and medical care of patients was
provided according to national guidelines.
Data collection
Data on demographic and socio-economic status were col-
lected at patient enrolment. Handgrip strength and body
composition data were collected at enrolment (before ART ini-
tiation), and at the 6th and 12th week post-ART initiation. The
time of starting ART was determined by factors outside the
investigators’ control and was a median of 21 (interquartile
range 15–30) d after referral for ART(16). Patients who did
not attend study visits were reminded by telephone or those
in Mwanza were also traced to their residences and encouraged
to come to clinics for follow-up measurements. Patients were
asked to fast overnight and were invited for anthropometry,
handgrip strength and body composition measurements in
the morning. While barefoot and with minimal clothing,
weight was determined to the nearest 0·1 kg using a digital
scale and height (baseline only) was measured to the nearest
0·1 cm using a stadiometer ﬁxed to the ofﬁce wall.
Anthropometric measurements were taken in triplicate and
medians were used during analysis. We assessed body compos-
ition using BIA using Tanita instrumentation (Tanita BC418)
as the primary method. In addition, we used D2O
(Cortecnet) and ADP (BodPod Model 2007A; Life
Measurement Instruments/COSMED) in subsamples, limited
by logistic and ﬁnancial constraints to Zambian participants, to
supplement BIA ﬁndings. All the methods assessed fat mass
(kg) and fat-free mass (kg) and, in addition, BIA also produced
results on trunk and segmental fat and fat-free mass, all
expressed in kg.
For the D2O technique, patients were asked to provide a
4-ml saliva sample (pre-dose saliva sample), after which they
were asked to take a previously prepared dose of 30 g D2O
using a straw from a 50-ml, screw-capped, leak-proof bottle.
Then they drank 100 ml of drinking water from the same bot-
tle to ensure all D2O was consumed. We collected two post-
dose saliva samples at 3 and 4 h. All samples were collected
into tightly capped cryogenic tubes and kept away from direct
sunlight. While waiting for post-dose sample collection,
patients were asked to refrain from walking, eating or drinking.
On the day of collection, samples were transported in cool
boxes to research laboratories at UTH, where they were stored
at −20°C pending transfer to the Zambian National Institute
for Scientiﬁc and Industrial Research in Lusaka for analysis.
Enrichment of D2O in saliva samples was determined by
Fourier Transform Infrared Spectrophotometer (FTIR
Model 8400s; Shimadzu). Post-dose enrichment used the
mean of the 3- and 4-h samples except where the 4-h enrich-
ment was appreciably higher than the 3-h, in which case only
the 4-h sample was used. Using post-dose enrichment data,
the dilution space and total body water (TBW) were calculated
using conventional formulae(23). Fat-free mass was calculated
as TBW/0·723(24) and fat mass was calculated as body weight
minus fat-free mass.
From BIA, D2O and ADP fat and fat-free mass, and height
measurements, fat mass index (FMI) was computed as fat
mass (kg)/(height (m2)), and fat-free mass index (FFMI) as
fat-free mass (kg)/(height (m2))(25). We used FMI and FFMI
in data management and fat and fat-free mass in evaluation
of the effect of intervention.
Handgrip strength was determined to the nearest 0·1 kg
using a digital dynamometer (Takei Scientiﬁc Instruments).
Four measurements were taken, with the mean of the two
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maximum measurements (one in each hand) reported. Venous
blood samples were taken for CD4 count (baseline and week
12 only)(16).
Data management and statistics
Data were double entered into OpenClinica databases in
Lusaka and into MySQL databases in Mwanza. Analyses
were conducted in STATA version 13. The D2O technique
is susceptible to chance errors resulting from incomplete dos-
ing, sample contamination, or unrecorded ﬂuid intake during
the equilibration period. Therefore, at baseline, we excluded
those with implausibly low fatness (fat mass <0 kg). We
further excluded those with implausibly high fatness, given
that the entire population had BMI <18·5 kg/m2; this resulted
in excluding those with FMI >6 kg/m2, or FMI >4 kg/m2 if
FFMI <11 kg/m2. For 6-week samples, we excluded those
with implausibly low fatness (fat mass<0 kg). We also
excluded those with poor agreement between BIA and ADP
(difference >±7 kg TBW). For 12-week samples, we excluded
those with implausibly low fatness (fat mass <0 kg), and
implausibly high fatness (FMI >8 kg/m2). We also excluded
those with poor agreement between BIA and ADP (difference
>±7 kg TBW). Based on this we excluded ﬁfty-six (10·5 %)
at baseline, twenty (8 %) at 6 weeks and twenty (9 %) at
12 weeks.
Fig. 1. Trial flow chart. * Number analysed for the effect of interventions. This may differ slightly with the actual number available at either 6 or 12 weeks because
analysis of the effect of intervention included participants with data at two time points, i.e. baseline and 6 weeks and 6 weeks and 12 weeks. ART, antiretroviral
therapy; LNS, lipid nutritional supplement; LNS-VM, lipid nutritional supplement with vitamins and minerals; BIA, bioelectrical impedance analysis (the main body
composition assessment method for the present study).
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Baseline characteristics were presented as means and stand-
ard deviations if continuous variables and percentages if cat-
egorical variables to assess comparability of treatment arms.
Socio-economic status was derived using principal component
analysis of a list of housing characteristics and durable
assets(16,26). Outcome measures (i.e. fat mass, fat-free mass
and handgrip strength) at 6 and 12 weeks post-ART were
compared using linear regression with ﬁnal estimate found
by adjusting for baseline values, sex, age, BMI, CD4 count
and socio-economic status.
In addition, since results at 6 and 12 weeks could be ana-
lysed only for patients who survived and attended 6- and
12-week visits, we also investigated treatment effects using
the detailed longitudinal data collected on all patients over
the course of the study. We used piece-wise mixed-effects
quadratic regression models to allow inclusion of data from
patients who died or were lost to follow-up up prior to 12
weeks. The additional ﬂexibility of cubic models and cubic
splines was assessed but ﬁt was considered adequate with
quadratic models(27). The time axis was split at the date of
starting ART, allowing two lines with differing slopes to be
ﬁtted per person while restricting these lines to join at the
date of ART initiation. For presentation, the marginal predic-
tions after starting ART were based on the median time, 21 d,
spent prior to starting ART; predictions pre-ART are not
graphed because of the complexity of showing different
lengths of time before ART.
To assess comparability of BIA against D2O and ADP
methods, we used the Bland–Altman method(28). Based on
this approach, we analysed differences (bias) in fat and fat-
free mass between BIA and the other methods and their
standard deviations (error) and calculated the limits of agree-
ment (bias ± 1·96 error) to determine if the degree to which
these methods differed was within a clinically acceptable
range. We further assessed the dependency of bias on the
mean of fat and fat-free mass for BIA and D2O and BIA
and ADP using linear regression. Among both sexes, the
acceptable range of error for fat and fat-free mass is thought
to be 2 to 4·5 kg for males and 1·5 to 3·6 kg for females(12).
Results
As shown in the trial ﬂow chart (Fig. 1), of 4573 participants
screened, 1876 were randomised, and 1815 included in the
analysis of the primary outcome(16), but only 1807 (897
allocated to LNS and 910 to LNS-VM) were included in the
present analysis because they had either body composition
or grip strength data or both. Of these patients, 1752 had
baseline data on handgrip strength and 1461, 479 and 498
had baseline body composition data based on BIA, D2O
and ADP, respectively. The mean participant age was 35·8
(range 18–78) years, 59·2 % had BMI <17 kg/m2, and 49·6
% were females. All baseline characteristics were equally
distributed between treatment arms (Table 1). From baseline
to 6 weeks, and 6 and 12 weeks, proportions not followed
up between LNS and LNS-VM groups on participants with
body composition measurements based on the three methods
(i.e. BIA, D2O and ADP) were not different (47·0 v. 44·5 %
(P = 0·34) and 9·5 v. 6·2 % (P = 0·12); 70·8 v. 70·8 %
(P = 0·99) and 37·7 v. 32·4 % (P= 0·65; and 72·1 v. 74·1 %
(P = 0·62) and 20·0 v. 17·2 % (P = 0·73), respectively).
Similarly, proportions of participants with handgrip strength
measurements not followed-up between baseline to 6 weeks
and 6 weeks to 12 months were not different between LNS
and LNS-VM groups (50·4 v. 47·9 % (P= 0·30) and 21·0 v.
21·2 % (P = 0·97), respectively). Overall, compared with
patients remaining in the study, those not followed up for
body composition and handgrip strength assessments at 6
and 12 weeks were more likely to be males, younger, thinner,
more immunocompromised, and not on tuberculosis treat-
ment, all factors associated with mortality in the cohort(29).
Table 1. Baseline characteristics of patients included in the evaluation of
the effect on Nutritional Support for African Adults Starting Antiretroviral
Therapy (NUSTART) intervention on secondary outcomes (i.e. handgrip
strength and body composition)*
(Mean values and standard deviations; numbers and percentages)
LNS (n 897) LNS-VM (n 910)
n % n %
Age (years)
Mean 35·7 35·9
SD 9·4 9·4
Female 456 50·8 440 48·4
Tuberculosis treatment 197 22·0 249 27·4
CD4 count (cells/μl)
Mean 135 140
SD 97 103
<100 cells/μl 390 43·5 395 43·4
BMI (kg/m2)
Mean 16·5 16·5
SD 1·4 1·3
<17 kg/m2 530 59·1 539 59·2
Socio-economic status
Lowest 197 22·0 166 18·2
Low 187 20·9 184 20·2
Middle 162 18·1 199 21·9
High 182 20·3 172 18·9
Highest 169 18·8 189 20·8
Marital status
Married 433 48·3 417 45·8
Widow/widower 107 11·9 95 10·4
Divorced/separated 243 12·3 264 29·0
Single 110 11·4 132 14·5
Living with partner 3 0·33 2 0·22
Occupation
Salaried 135 15·1 134 14·7
Self-employed 458 51·1 484 53·2
Housewife 97 10·8 86 9·5
Student 9 1·0 9 1·0
Unemployed 197 22·0 197 21·7
Education level
None 173 19·3 168 18·5
Primary 516 57·6 526 57·8
Secondary 182 20·3 192 21·1
University/tertiary 25 2·8 24 2·6
Study site
Lusaka 548 61·1 556 61·1
Mwanza 349 38·9 354 38·9
LNS, lipid nutritional supplement; LNS-VM, lipid nutritional supplement with added
vitamins and minerals; CD4, cluster of differentiation 4.
* Of the participants, 1752 had baseline data on handgrip strength, and baseline
body composition data were collected on 1461 using bioelectrical impedance ana-
lysis, 479 using the deuterium (2H) diluted water method and 498 using air displace-
ment plethysmography.
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Table 2 presents body composition and handgrip strength
data at baseline, and at 6 and 12 weeks by treatment arm.
Supplementary Table S2 presents the same information
among patients with data from all three body composition
assessment methods. Effects of LNS-VM v. LNS on changes
in body composition between baseline and 6 weeks of ART
are shown in Table 3 and similar results for changes between
6 and 12 weeks of ART are shown in Table 4. At the end of
6 weeks of ART, patients given LNS-VM tended to have higher
fat mass than those randomised to LNS (0·4 (95 % CI 0·05,
0·8) kg); although the point estimate was highest for fat mass
assessed by D2O, the effect was signiﬁcant only for fat mass
by BIA, possibly because of the larger number of participants
assessed by this method. Treatment arm showed no association
with change in fat-free mass. Between 6 and 12 weeks of ART
there were no signiﬁcant differences between treatment arms in
fat mass and fat-free mass change although the point estimates
suggested higher fat-free mass in the LNS-VM group. Similar
results for trunk and limb composition by BIA were seen as
for total body tissue masses by BIA. In a sensitivity analysis
involving patients with body composition measurements by
all three methods (twenty-two patients at 6 weeks and eighteen
at 12 weeks), we found no effect of the intervention on fat and
fat-free mass (Supplementary Tables S3 and S4).
At the end of 6 weeks post-ART, patients in the LNS-VM
group had 0·72 (95 % CI −0·03, 1·5) kg greater handgrip
Table 2. Fat mass, fat-free mass and grip strength at baseline and at 6 and 12 weeks after starting antiretroviral therapy
(Mean values and standard deviations)
Baseline Week 6 Week 12
LNS LNS-VM LNS LNS-VM LNS LNS-VM
n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD
Fat mass (kg)
Total by D2O 236 5·9 2·8 243 6·0 2·7 115 8·1 3·2 113 8·6 3·4 96 8·9 4·6 105 9·7 4·6
Total by ADP 251 6·9 2·8 247 6·7 3·0 108 8·0 3·1 102 9·0 3·5 83 9·7 4·1 89 9·9 3·9
Total by BIA 738 5·0 2·8 723 4·9 2·8 436 6·8 3·3 461 6·9 3·3 399 7·6 3·5 437 7·6 3·5
Truncal 738 2·1 1·6 723 2·1 1·5 435* 3·0 1·9 461 3·1 1·9 399 3·5 2·1 437 3·5 2·1
Limb 738 3·0 1·8 723 3·0 1·9 436 3·9 2·0 461 3·9 2·0 399 4·2 2·1 437 4·2 2·1
Fat-free mass (kg)
Total by D2O 236 39·8 5·9 243 39·3 6·0 115 39·7 5·4 113 40·6 6·2 96 40·6 6·0 105 40·7 6·4
Total by ADP 251 38·7 5·6 247 38·9 5·7 108 39·4 5·5 102 39·4 5·4 83 39·7 5·9 89 40·9 5·7
Total by BIA 738 39·6 6·5 723 40·0 6·2 436 41·4 6·7 461 41·6 6·6 399 41·8 6·6 437 42·6 7·1
Truncal 738 21·9 3·0 723 22·1 3·0 435* 23·1 3·4 461 23·2 3·3 399 23·3 3·3 437 23·8 3·6
Limb 738 17·5 3·3 723 17·7 3·3 436 18·2 3·5 461 18·3 3·5 399 18·4 3·5 437 18·7 3·7
Grip strength (kg) 863 19·4 6·8 889 19·9 7·0 450 21·1 6·8 476 22·3 7·0 371 22·8 7·1 406 23·6 7·0
LNS, lipid nutritional supplement; LNS-VM, lipid nutritional supplement with vitamins and minerals; D2O, deuterium (
2H) diluted water method; ADP, air displacement plethysmo-
graphy; BIA, bioelectrical impedance analysis.
* One observation is missing.
Table 3. Effects of intervention on the change in body composition and grip strength between baseline and 6 weeks of antiretroviral therapy (ART)
(Mean values and 95 % confidence intervals)
Change between baseline and 6 weeks of ART
LNS LNS-VM Difference between arms*
Adjusted difference
between arms†
n Mean 95 % CI n Mean 95 % CI Mean 95 % CI P Mean 95 % CI P
Fat mass (kg)
Total by D2O 69 1·7 0·9, 2·5 71 2·5 1·7, 3·2 0·7 −0·4, 1·8 0·22 0·7 −0·4, 1·9 0·21
Total by ADP 70 1·2 0·6, 1·9 64 1·6 1·0, 2·0 0·3 −0·6, 1·2 0·50 0·4 −0·5, 1·3 0·42
Total by BIA 391 1·5 1·3, 1·7 401 1·9 1·7–2·2 0·4 0·06, 0·8 0·02 0·4 0·05, 0·8 0·02
Truncal 390‡ 0·8 0·6, 0·9 401 1·0 0·9, 1·2 0·2 0·02, 0·5 0·03 0·2 0·01, 0·4 0·04
Limb 391 0·7 0·6, 0·8 401 0·8 0·7, 0·9 0·1 −0·02, 0·3 0·09 0·1 −0·02, 0·3 0·09
Fat-free mass (kg)
Total by D2O 69 1·3 0·5, 2·2 71 1·1 0·2, 2·0 −0·2 −1·4, 1·0 0·77 0·2 −1·0, 1·5 0·76
Total by ADP 70 1·0 0·5, 1·6 64 0·9 0·2, 1·5 −0·1 −0·9, 0·7 0·74 −0·2 −1·0, 0·7 0·70
Total by BIA 391 1·5 1·1, 1·9 401 1·8 1·5, 2·1 0·2 −0·3, 0·7 0·42 0·2 −0·3, 0·7 0·51
Truncal 390‡ 1·0 0·9, 1·3 401 1·1 0·9, 1·3 0·07 −0·2, 0·3 0·57 0·06 −0·2, 0·3 0·66
Limb 391 0·7 0·5, 0·8 401 0·7 0·6, 0·9 0·03 −0·2, 0·2 0·77 0·01 −0·2, 0·2 0·90
Grip strength (kg) 428 1·2 0·7, 1·7 463 1·9 1·4, 2·4 0·73 −0·02, 1·5 0·06 0·72 −0·03, 1·5 0·06
LNS, lipid nutritional supplement; LNS-VM, lipid nutritional supplement with vitamins and minerals; D2O, deuterium (
2H) diluted water method; ADP, air displacement plethysmo-
graphy; BIA, bioelectrical impedance analysis; CD4, cluster of differentiation 4.
* Difference between change over time, adjusted for age and sex.
†Difference between change over time, adjusted for age, sex, baseline CD4, baseline BMI and socio-economic status.
‡One observation missing.
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strength regain compared with patients in the LNS arm after
adjusting for sex, age, baseline CD4, baseline handgrip
strength, and socio-economic status, although this was margin-
ally signiﬁcant (P = 0·06) (Table 3). However, at 12 weeks,
LNS-VM intervention did not have any effect on handgrip
strength (−0·28 (95 % CI −1·1, 0·5) kg; P = 0·48) (Table 4).
As shown in Figs 2 and 3, in the longitudinal analysis includ-
ing all patients in the course of the study we found no treat-
ment effect of the intervention on handgrip grip strength
(P= 0·71 overall, P = 0·87 pre-ART and P = 0·65 post-ART),
fat mass (P = 0·16 overall, P= 0·86 pre-ART and P = 0·39
post-ART), or fat-free mass (P = 0·66 overall, P = 0·43
pre-ART and P = 0·76 post-ART).
Fat mass measured by BIA tended to be lower than when
measured by ADP or D2O and fat-free mass tended to be
correspondingly higher and the limit of agreements were
−8·0 to 4·6 kg and −7·8 to 2·4 kg for fat mass and −4·8
to 7·8 kg and −3·0 to 7·2 kg kg for fat-free mass, respectively
(Fig. 4).
Discussion
In the NUSTART trial, we found beneﬁts of the vitamin and
mineral supplementation for CD4 count and some anthropo-
metric measures: calf and mid-upper arm circumferences and
triceps skinfold(16,17). Here we investigated the effect of the
vitamin and mineral intervention on body composition
assessed by three different methods as well as handgrip
strength. We found that the LNS-VM intervention led to an
increase in BIA-assessed fat mass at 6 but not 12 weeks.
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Fig. 2. Effects of the Nutritional Support for African Adults Starting Antiretroviral Therapy (NUSTART) intervention (lipid-based nutritional supplement (LNS; ----) or
LNS with added vitamins and minerals (LNS-VM; –––) on handgrip strength during antiretroviral therapy (ART). Values are means, with standard deviations repre-
sented by vertical bars. Difference between LNS-VM and LNS: P=0·71.
Table 4. Effects of intervention on the change in body composition and grip strength between 6 and 12 weeks of antiretroviral therapy (ART)
(Mean values and 95 % confidence intervals)
Change between 6 and 12 weeks of ART
LNS LNS-VM Difference between arms*
Adjusted difference
between arms†
n Mean 95 % CI n Mean 95 % CI Mean 95 % CI P Mean 95 % CI P
Fat mass (kg)
Total by D2O 43 1·1 0·04, 2·3 48 1·6 0·4, 2·7 0·4 −1·2, 1·9 0·64 0·8 −0·8, 2·4 0·32
Total by ADP 56 0·7 −0·1, 1·5 53 0·4 −0·1, 1·0 −0·3 −1·2, 0·7 0·58 −0·3 −1·3, 0·8 0·62
Total by BIA 354 0·9 0·7, 1·2 376 0·8 0·6, 1·0 −0·14 −0·4, 1·1 0·31 −0·2 −0·0·5, 0·1 0·20
Truncal 353‡ 0·6 0·4, 0·7 376 0·4 0·3, 0·6 −0·1 −0·3, −0·1 0·19 −0·1 −0·3, 0·04 0·13
Limb 354 0·4 0·3, 0·4 376 0·4 0·3, 0·4 0·003 −0·1, 0·1 0·95 −0·01 −0·1, 0·09 0·84
Fat-free mass (kg)
Total by D2O 43 −0·2 −1·4, 0·9 48 0·4 −0·7, 1·5 0·6 −1·0, 2·0 0·48 0·4 −1·3, 2·0 0·67
Total by ADP 56 0·0 −0·6, 0·6 53 0·7 0·1, 1·2 0·6 −0·2, 1·4 0·12 0·7 −0·2, 1·6 0·12
Total by BIA 354 0·3 0·05, 0·6 376 0·4 0·1, 0·6 0·1 −0·3, 0·5 0·64 0·1 −0·3, 0·4 0·71
Truncal 353‡ 0·2 0·1, 0·4 376 0·3 0·1, 0·4 0·06 −0·1, 0·3 0·54 0·05 −0·1, 0·3 0·63
Limb 354 0·1 −0·0, 0·3 376 0·15 0·03, 0·3 0·03 −0·1, 0·2 0·76 0·02 −0·1, 0·2 0·82
Grip strength (kg) 338 1·37 0·8, 1·9 365 1·1 0·5, 1·6 −0·29 9 −1·1, 0·5 0·47 −0·28 −1·1, 0·5 0·48
LNS, lipid nutritional supplement; LNS-VM, lipid nutritional supplement with vitamins and minerals; D2O, deuterium (
2H) diluted water method; ADP, air displacement plethysmo-
graphy; BIA, bioelectrical impedance analysis; CD4, cluster of differentiation 4.
* Difference between change over time, adjusted for age and sex.
†Difference between change over time, adjusted for age, sex, baseline CD4, baseline BMI and socio-economic status.
‡One observation missing.
7
journals.cambridge.org/jns
D
ow
nl
oa
de
d 
fr
om
 h
tt
ps
:/
/w
w
w
.c
am
br
id
ge
.o
rg
/c
or
e.
 U
C
L,
 In
st
itu
te
 o
f E
du
ca
tio
n,
 o
n 
04
 Ju
n 
20
19
 a
t 1
5:
50
:0
7,
 s
ub
je
ct
 to
 th
e 
C
am
br
id
ge
 C
or
e 
te
rm
s 
of
 u
se
, a
va
ila
bl
e 
at
 h
tt
ps
:/
/w
w
w
.c
am
br
id
ge
.o
rg
/c
or
e/
te
rm
s.
 h
tt
ps
:/
/d
oi
.o
rg
/1
0.
10
17
/j
ns
.2
01
9.
15
ADP and D2O measures of fat mass showed similar point
estimates of the changes but were not statistically signiﬁcant,
possibly due to lower sample size. The intervention had no
effect on fat-free mass, an outcome measure associated with
improved physical functions(30) and reduced mortality(7). The
intervention had a borderline signiﬁcant effect on handgrip
strength at 6 weeks but this was not sustained at 12 weeks.
Based on longitudinal analysis, the intervention did not alter
any outcome measures throughout the follow-up period.
Several possible mechanisms could have mediated the effect
on fat mass found with BIA, including treatment group differ-
ences in food intake or physical activity, neither of which was
directly measured in our study. In theory, there could have
been an increase in food intake in the LNS-VM group as a
result of increase in appetite secondary to higher intake of
vitamins and minerals as has been shown previously in
HIV-infected South African children(31). However, in
NUSTART we found no effect of the intervention on appe-
tite(17). A higher intake of vitamins and minerals leading to
improved muscle functions, as supported by our data on
grip strength, should have resulted in increased rather than
reduced energy expenditure, so effects on fat mediated by dif-
ferential physical activity seem unlikely. As an additional
potential mechanism, the persistence of inﬂammation could
have favoured fat accretion over fat-free tissue accretion as
seen following severe infections(32,33). We have shown that
patients in this cohort had severe inﬂammation which had
not appreciably decreased by 6 weeks of ART and which
may have limited fat-free mass but not fat mass regain(34).
The acute-phase response due to severe inﬂammation may
be a major factor explaining the lack of tissue repletion during
nutritional trials of HIV patients(35). Despite high vitamin and
mineral intake, the acute-phase response to infection may have
depressed the serum or plasma concentrations of vitamins A,
C and E and folate, and Zn and Se(36,37), possibly reducing
their availability for tissue synthesis in the ﬁrst weeks of
ART initiation when the acute-phase response remains high.
Results from previous nutritional trials provide support for
this possible explanation. Among tuberculosis patients, a
population with as severe inﬂammation as HIV patients, nutri-
tional supplementation did not lead to full nutritional recovery
due to impaired anabolism during treatment(32,33). Among
(a)
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Fig. 3. Effects of the Nutritional Support for African Adults Starting Antiretroviral Therapy (NUSTART) intervention (lipid-based nutritional supplement (LNS; ----) or
LNS with added vitamins and minerals (LNS-VM; –––) on body composition changes during antiretroviral therapy (ART). Values are means, with standard deviations
represented by vertical bars. (a) Effects of NuSTART intervention on fat mass during ART. Difference between LNS-VM and LNS: P=0·16. (b) Effects of NUSTART
intervention on fat-free mass during ART. Difference between LNS-VM and LNS: P=0·66.
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apparently healthy HIV-infected individuals, a multi-
micronutrient supplement given for 3 months did not result
in increased plasma Fe and Zn among those who had inﬂam-
mation, but led to increased levels among those who had no
inﬂammation(38,39). In a nutritional supplementation trial in
Ethiopia, at 3 months of follow-up there was a higher increase
in fat-free mass in a subgroup of patients with viral suppres-
sion(10), compared with those without viral suppression, sug-
gesting that reduction of inﬂammation may have contributed
to the accrual of fat-free mass in this subgroup.
Other factors limiting accrual of fat-free mass in the present
study may include low compliance with interventions(16) and
poor nutrient absorption. Although the supplement contained
high amounts of growth nutrients including Zn, phosphate
and Mg, bioavailability may have been limited since in the
study area maize meal and legumes are the staple foods(40)
and have high content of phytates which tend to chelate metals
like Zn, Ca and Mg resulting in insoluble complexes which are
poorly absorbed(41,42). We did not study nutrient absorption
properties in this study. Lastly, although the supplement
contained many essential micronutrients in high amounts,
the amounts of growth nutrients including Zn provided may
have been inadequate to support additional synthesis of tissues
at the time of very high demand.
In the NUSTART study we had hypothesised that the
LNS-VM would have led to signiﬁcant repletion of fat-free
mass and help improve physical functions and work cap-
acity(30) and reduce mortality(7). In contrast, the intervention
led to an increment in adipose tissue rather than fat-free
mass and to no mortality reduction(16). It is possible that at
the time of ART initiation when the inﬂammation is severe,
regaining fat mass rather than fat-free mass is a more appro-
priate short-term survival strategy in malnourished HIV
patients starting ART since fat mass provides energy needed
to sustain inﬂammation(43), a process aimed at modulating
HIV infection. This is consistent with recent ﬁndings from a
systematic review which found that patients starting ART
with CD4 counts <350 cells/mm3 have greater risk of devel-
oping obesity during treatment in comparison with patients
starting ART with higher CD4 counts(44). Adiposity is
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Fig. 4. Bland–Altman plots of fat mass and fat-free mass comparing bioelectrical impedance analysis (BIA) with the deuterium (2H) diluted water (D2O) method and
air displacement plethysmography (ADP) technique. (a) Plot with regression line of difference v. mean fat mass measured by BIA and D2O. The bias was –1·7 kg
(±3·2) and the limit of agreement was between –8·0 and 4·6 kg. (b) Plot with regression line of difference v.mean fat mass measured by BIA and ADP. The bias was –
2·7 kg (±2·5) and the limit of agreement was between –7·8 and 2·4 kg. (c) Plot with regression line of difference v.mean fat-free mass measured by BIA and D2O. The
bias was 1·5 kg (±3·2) and the limit of agreement was between –4·8 and 7·8 kg. (d) Plot with regression line of difference v. mean fat-free mass measured by BIA and
ADP. The bias was 2·1 kg (±2·6) and the limit of agreement was between –3·0 and 7·2 kg.
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characterised by a trade-off between short-term beneﬁts and
long-term risks(45). Thus, in the long run, patients starting
ART when malnourished may have increased risk for develop-
ing non-communicable diseases including diabetes and hyper-
tension. In fact, several large cohorts have shown that
HIV-infected patients have higher risk of diabetes and hyper-
tension partly explained by nutritional recovery during
ART(46–48).
The beneﬁcial effect on handgrip strength of about 700 g,
although only marginally signiﬁcant, may be of clinical and sur-
vival importance(14,49). The increase may reﬂect improvements
in muscle functions rather than muscle size since we did not
see any effect on fat-free mass. Irrespective of the mechanisms
involved, this seemingly positive effect on grip strength in
the present and other trials(10,50) suggests that nutritional inter-
ventions with added vitamins and minerals may help increase
physical strength and work capacity of HIV-infected
patients(14).
Our results for the different body composition methods
showed that BIA tended to give lower values for fat mass
than D2O or ADP but that this did not appreciably affect
the group differences over time. Although limits of agreement
were wide, the biases and errors were within acceptable
ranges(12). In an Ethiopian study there was no overall differ-
ence between BIA and D2O but BIA tended to overestimate
fat-free mass at low fat-free mass(51). Among Senegalese
HIV-infected adults, the bias between BIA and D2O methods
was considered relatively small such that BIA, the simpler and
cheaper method, was acceptable(52). Similarly, BIA, when com-
pared with D2O, was found to be acceptable for HIV-infected
and uninfected breastfeeding South African women(53).
Overall, it appears that, in spite of concerns, BIA is a useful
tool for measuring body composition even in seriously ill,
malnourished HIV-infected patients and particularly in low-
income settings where resources may be a major limitation
in using superior methods. The ﬁndings in the present analysis
and previous studies(9) suggest that further research is required
to understand what should be provided to HIV patients in
order to achieve optimal nutritional recovery.
The strengths of the present trial were that it was rando-
mised and double-blinded, had large sample size and body
composition was assessed using BIA and other better methods
rather than anthropometry alone. However, we did not obtain
direct measures of food intake and energy expenditure and
compliance with nutritional intervention was modest and
assessed using reported information. This limited the scope
of our data interpretation. In addition, the study was con-
ducted 5 years ago and during this period changes in ART
regimens and eligibility criteria have occurred which could
limit the external validity of our study ﬁndings. Future studies
should include mechanistic substudies to be able to better
explain the ﬁndings.
Conclusions
Added high doses of vitamins and minerals led to a higher
regain of fat mass but not fat-free mass and borderline signiﬁ-
cant effect on handgrip strength at 6 weeks post-ART. Taken
together, these ﬁndings suggest the need for a well-considered
approach in providing nutritional supplements high in vita-
mins and minerals to malnourished HIV-infected patients
starting ART in sub-Saharan Africa. Further research on
appropriate intervention timing, micronutrients requirements,
optimal regimens and uptake monitoring is needed to guide
the design of future nutritional intervention trials in HIV
patients.
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